Monday, November 9, 2026

USD/CHF Bullish By 1% In The Last 21 Sessions

ViaNews Editorial Team

February 26, 2024

USD/CHF Bullish By 1% In The Last 21 Sessions

(VIANEWS) - USD/CHF (USDCHF) has been up by 1.63% for the last 21 sessions. At 01:06 EST on Monday, 26 February, USD/CHF (USDCHF) is $0.88.

USD/CHF's yearly highs and lows, it's 5.762% up from its 52-week low and 6.674% down from its 52-week high.

Volatility

USD/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.02%, a positive 0.08%, and a positive 0.34%, respectively.

USD/CHF's highest amplitude of average volatility was 0.18% (last week), 0.34% (last month), and 0.34% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CHF's Forex is considered to be overbought (>=80).

News about

  • Eur/usd weekly forecast: speculators should prepare for volatility this week - 25 February 2024. According to DailyForex on Sunday, 25 February, "S GDP numbers are stronger than expected, this could set off an additional wave of EUR/USD selling.", "The EUR/USD will see its range certainly become wider based on the results from the wave of reactions caused by the U."
  • Eur/usd loses momentum above the 1.0800 mark amid modest rebound of US dollar. According to FXStreet on Monday, 26 February, "Traders will take cues from the data and find trading opportunities around the EUR/USD pair.", "The weaker-than-expected data might weigh on the US Dollar and act as a tailwind for the EUR/USD pair. "

More news about USD/CHF (USDCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com